Cargando…

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia

Antifungal prophylaxis is recommended to prevent invasive fungal disease caused by Candida spp., Aspergillus spp., and Pneumocystis jirovecii in patients at risk for opportunistic infections, such as allogeneic blood or marrow transplant recipients, patients with hematological disease undergoing che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miesel, Lynn, Cushion, Melanie T., Ashbaugh, Alan, Lopez, Santiago R., Ong, Voon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092522/ https://www.ncbi.nlm.nih.gov/pubmed/33318018 http://dx.doi.org/10.1128/AAC.01992-20

Ejemplares similares

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models
por: Cushion, Melanie T., et al.
Publicado: (2021)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

The Effects of Sex and Strain on Pneumocystis murina Fungal Burdens in Mice
por: Macioce-Tisdale, Nikeya L., et al.
Publicado: (2022)

Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection
por: Cushion, Melanie T., et al.
Publicado: (2010)

A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
por: Liu, Guan-Sheng, et al.
Publicado: (2018)

Treatment and Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients
por: Smith, Don, et al.
Publicado: (2012)

The Promise of Lung Organoids for Growth and Investigation of Pneumocystis Species
por: Tisdale-Macioce, Nikeya, et al.
Publicado: (2021)

Correction to: A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
por: Liu, Guan-Sheng, et al.
Publicado: (2019)

Anidulafungin Treatment Blocks the Sexual Cycle of Pneumocystis murina and Prevents Growth and Survival without Rescue by an Alternative Mode of Replication
por: Cushion, Melanie T., et al.
Publicado: (2022)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

Noninvasive Method for Monitoring Pneumocystis carinii Pneumonia
por: Linke, Michael J., et al.
Publicado: (2003)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
por: Wiederhold, Nathan P, et al.
Publicado: (2009)

Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review
por: Sierra, Caroline M., et al.
Publicado: (2022)

Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids
por: Lazzarini, Cristina, et al.
Publicado: (2018)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

Is sex necessary for the proliferation and transmission of Pneumocystis?
por: Hauser, Philippe M., et al.
Publicado: (2018)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
por: Martin, Judith M., et al.
Publicado: (2017)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Gene Expression of Pneumocystis murina after Treatment with Anidulafungin Results in Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for Ascus Formation for Proliferation
por: Cushion, Melanie T., et al.
Publicado: (2018)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Invasive Aspergillosis and Candidiasis in a Patient with Plasma Cell Myeloma
por: Khadwal, Alka, et al.
Publicado: (2023)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

Assembly and Annotation of Pneumocystis jirovecii from the Human Lung Microbiome
por: Cushion, Melanie T., et al.
Publicado: (2013)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

Are Members of the Fungal Genus Pneumocystis (a) Commensals; (b) Opportunists; (c) Pathogens; or (d) All of the Above?
por: Cushion, Melanie T.
Publicado: (2010)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_91et7jkvka6attmmhtn6trrf6k